Frequency of Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Expression in Gastric Adenocarcinoma in Rehman Medical Institute Peshawar.
To investigate the frequency of Human Epidermal Growth Factor Receptor 2 over expression in gastric adenocarcinoma by immunohistochemistry and to find the association of its expression with clinicopathological parameters. . The descriptive cross-sectional study was conducted at Rehman Medical Institute, Peshawar, Pakistan, from January to December 2016, and comprised consecutive formalin-fixed and paraffin-embedded samples of gastric adenocarcinoma. The cases were scored for Human Epidermal Growth Factor Receptor 2 expression according to criteria cited in Trastuzumab for Gastric Cancer trial. Correlation of the expression with different clinicopathological parameters was determined. SPSS 23 was used for data analysis. Of the 55 cases, 49(89%) were biopsies and 6(11%) were gastrectomies. Among the patients whose samples were tested, 41(74.5%) were male. The overall mean age was 59.16}12.58 years (range: 38-95 years). Human Epidermal Growth Factor Receptor 2 overexpression (3+) was present in 19(34.5%) cases.Out of 21(38.2%) cases of moderately differentiated adenocarcinoma, 10(47.6%) showed overexpression. It was commonest in tumours of the fundus area 7(31.6%). No association of the expression was found with tumour's histological grade and location, or with patient's gender and age (p>0.05 each).. More than one-third of the sample had overexpression of Human Epidermal Growth Factor Receptor 2.